Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupGastroenterologic OncologySarcomasDiseaseGastrointestinal Stroma TumorSubgroupPDGFRA D842V mutationICD10C15.-C16.-C17.-C18.-C48.-MeSHGastrointestinal Stromal TumorsSequenceIMAT400/BINI30, GIST, C1 (PID2009) -|- C2+ (PID2010)ChemotherapyChemo-substanceAvapritinibBinimetinibImatinibRegorafenibRipretinibSunitinibChemo-substanceAvapritinibBinimetinibImatinibRegorafenibRipretinibSunitinibChemo-substanceAvapritinibBinimetinibImatinibRegorafenibRipretinibSunitinibChemo-substanceAvapritinibBinimetinibImatinibRegorafenibRipretinibSunitinibNo. Substances12 RadiotherapySupportive therapySupportive substanceDexamethasoneGranisetronSupportive substanceDexamethasoneGranisetronSupportive substanceDexamethasoneGranisetronSupportive substanceDexamethasoneGranisetronNo. Substances2Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineseveral possibleThird line Therapy phaseTherapy intentioncurativepalliativeRisksAlopeciaAnemia Hb below 8g/dlArthalgiaAstheniaCardiotoxicityCNS ToxicityConstipationDiarrheaEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueHand-Foot SyndromeHemorrhageHyperbilirubinemiaHyperkalemiaHypertensionHypertriglyceridemiaHypokalemiaHyponatremiaHypophosphatemiaHypothyroidismIncrease AminotransferasesIncrease Creatinine PhosphokinaseMucositisMyalgiasNauseaNeutropeniaOral MucositisPleural EffusionPruritusRashSeizuresThrombocytopenia below 50 000/µl only studiesPublicationAuthorBlay JYChi PDemetri GHeinrich MCJoensuu HDiseasefortgeschrittener, nicht operabler gastrointestinaler Stromatumor, Zweitlinie nach Imatinib, ECOG 0-1fortgeschrittener gastrointestinaler Stromatumor, Erstlinie oder Imatinib adjuvant, ECOG 0-1gastrointestinaler Stromatumor, adjuvantGastrointestinaler Stromatumor, inoperabel, PDGFRA D842V-mutiert, ECOG 0-2metastasierter, inoperabler gastrointestinaler Stromatumor nach Imatinib und Sunitinib, ECOG 0-1nichtresezierbarer oder metastasierter gastrointestinaler Stromatumor, CD117 expressionierend, ECOG < 3nichtresezierbarer oder metastasierter GIST, nach Therapie mit 3 oder mehr Kinase-Hemmern, einschließlich Imatinib, Sunitinib und RegorafenibOriginCentre Leon Berard, Lyon, France, INVICTUS trialDepartment of Oncology, Helsinki University Central Hospital, FinnlandFrom the Dana–Farber Cancer Institute and Harvard Cancer Center, BostonHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New YorkKnight Cancer Institute, Portland, USA, NAVIGATOR trialLudwig Center at Dana-Farber Cancer Institute and Harvard Medical School, Boston, USALudwig Center at Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA, GRID trialProtocols in Revision 8 protocols foundProtocols under revision.Avapritinib 300, Gastrointestinal Stroma Tumor (PID1689 V1.1)Imatinib 400 / Binimetinib 30, Gastrointestinal Stromal Tumor, cycle 1 (PID2009 V1.0)Imatinib 400 / Binimetinib 30, Gastrointestinal Stromal Tumor, cycle 2+ (PID2010 V1.0)Imatinib 400, Gastrointestinal Stroma Tumor (PID796 V1.1)Imatinib 400, Gastrointestinal Stroma Tumor, adjuvant (PID569 V1.1)Regorafenib 160, Gastrointestinal Stroma Tumor (PID795 V1.0)Ripretinib 150, Gastrointestinal Stroma Tumor (PID1955 V1.0)Sunitinib 50, Gastrointestinal Stroma Tumor (PID794 V1.0)
